These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23197398)

  • 1. Impact of systolic dysfunction in genotyped hypertrophic cardiomyopathy.
    Fujino N; Konno T; Hayashi K; Hodatsu A; Fujita T; Tsuda T; Nagata Y; Kawashiri MA; Ino H; Yamagishi M
    Clin Cardiol; 2013 Mar; 36(3):160-5. PubMed ID: 23197398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function.
    van Dijk SJ; Paalberends ER; Najafi A; Michels M; Sadayappan S; Carrier L; Boontje NM; Kuster DW; van Slegtenhorst M; Dooijes D; dos Remedios C; ten Cate FJ; Stienen GJ; van der Velden J
    Circ Heart Fail; 2012 Jan; 5(1):36-46. PubMed ID: 22178992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertrophic cardiomyopathy in myosin-binding protein C (
    Adalsteinsdottir B; Burke M; Maron BJ; Danielsen R; Lopez B; Diez J; Jarolim P; Seidman J; Seidman CE; Ho CY; Gunnarsson GT
    Open Heart; 2020; 7(1):e001220. PubMed ID: 32341788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy.
    Rosmini S; Biagini E; O'Mahony C; Bulluck H; Ruozi N; Lopes LR; Guttmann O; Reant P; Quarta CC; Pantazis A; Tome-Esteban M; Mckenna WJ; Rapezzi C; Elliott PM
    Heart; 2017 Feb; 103(4):300-306. PubMed ID: 27798053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular magnetic resonance of mitral valve length in hypertrophic cardiomyopathy.
    Tarkiainen M; Sipola P; Jalanko M; Heliö T; Laine M; Järvinen V; Häyrinen K; Lauerma K; Kuusisto J
    J Cardiovasc Magn Reson; 2016 Jun; 18(1):33. PubMed ID: 27259862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations.
    Michels M; Soliman OI; Kofflard MJ; Hoedemaekers YM; Dooijes D; Majoor-Krakauer D; ten Cate FJ
    JACC Cardiovasc Imaging; 2009 Jan; 2(1):58-64. PubMed ID: 19356534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.
    Viswanathan SK; Sanders HK; McNamara JW; Jagadeesan A; Jahangir A; Tajik AJ; Sadayappan S
    PLoS One; 2017; 12(11):e0187948. PubMed ID: 29121657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.
    Calore C; De Bortoli M; Romualdi C; Lorenzon A; Angelini A; Basso C; Thiene G; Iliceto S; Rampazzo A; Melacini P
    J Med Genet; 2015 May; 52(5):338-47. PubMed ID: 25740977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy.
    Chida A; Inai K; Sato H; Shimada E; Nishizawa T; Shimada M; Furutani M; Furutani Y; Kawamura Y; Sugimoto M; Ishihara J; Fujiwara M; Soga T; Kawana M; Fuji S; Tateno S; Kuraishi K; Kogaki S; Nishimura M; Ayusawa M; Ichida F; Yamazawa H; Matsuoka R; Nonoyama S; Nakanishi T
    Heart Vessels; 2017 Jun; 32(6):700-707. PubMed ID: 27885498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics and Long-Term Outcome of Hypertrophic Cardiomyopathy in Individuals With a MYBPC3 (Myosin-Binding Protein C) Founder Mutation.
    van Velzen HG; Schinkel AFL; Oldenburg RA; van Slegtenhorst MA; Frohn-Mulder IME; van der Velden J; Michels M
    Circ Cardiovasc Genet; 2017 Aug; 10(4):. PubMed ID: 28794111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The R820W mutation in the MYBPC3 gene, associated with hypertrophic cardiomyopathy in cats, causes hypertrophic cardiomyopathy and left ventricular non-compaction in humans.
    Ripoll Vera T; Monserrat Iglesias L; Hermida Prieto M; Ortiz M; Rodriguez Garcia I; Govea Callizo N; Gómez Navarro C; Rosell Andreo J; Gámez Martínez JM; Pons Lladó G; Cremer Luengos D; Torres Marqués J
    Int J Cardiol; 2010 Nov; 145(2):405-407. PubMed ID: 20542340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial Deformation Analysis in
    Höller V; Seebacher H; Zach D; Schwegel N; Ablasser K; Kolesnik E; Gollmer J; Waltl G; Rainer PP; Verheyen S; Zirlik A; Verheyen N
    Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction.
    Funada A; Kanzaki H; Noguchi T; Morita Y; Sugano Y; Ohara T; Hasegawa T; Hashimura H; Ishibashi-Ueda H; Kitakaze M; Yasuda S; Ogawa H; Anzai T
    Heart Vessels; 2016 May; 31(5):758-70. PubMed ID: 25820658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Prevalence of Systolic Dysfunction in MYBPC3 Versus MYH7-Related Hypertrophic Cardiomyopathy.
    Beltrami M; Fedele E; Fumagalli C; Mazzarotto F; Girolami F; Ferrantini C; Coppini R; Tofani L; Bertaccini B; Poggesi C; Olivotto I
    Circ Genom Precis Med; 2023 Aug; 16(4):363-371. PubMed ID: 37409452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy.
    Ho CY; Carlsen C; Thune JJ; Havndrup O; Bundgaard H; Farrohi F; Rivero J; Cirino AL; Andersen PS; Christiansen M; Maron BJ; Orav EJ; Køber L
    Circ Cardiovasc Genet; 2009 Aug; 2(4):314-21. PubMed ID: 20031602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy.
    Hamada T; Kubo T; Kitaoka H; Hirota T; Hoshikawa E; Hayato K; Shimizu Y; Okawa M; Yamasaki N; Matsumura Y; Yabe T; Takata J; Doi YL
    Clin Cardiol; 2010 Jul; 33(7):E24-8. PubMed ID: 20641106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of apical cavity obliteration in apical hypertrophic cardiomyopathy.
    Kim H; Park JH; Won KB; Yoon HJ; Park HS; Cho YK; Nam CW; Han S; Hur SH; Kim YN; Kim KB
    Heart; 2016 Aug; 102(15):1215-20. PubMed ID: 26969633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.
    Sedaghat-Hamedani F; Kayvanpour E; Tugrul OF; Lai A; Amr A; Haas J; Proctor T; Ehlermann P; Jensen K; Katus HA; Meder B
    Clin Res Cardiol; 2018 Jan; 107(1):30-41. PubMed ID: 28840316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The progression of left ventricular systolic and diastolic dysfunctions in hypertrophic cardiomyopathy: clinical and prognostic significance.
    Pinamonti B; Merlo M; Nangah R; Korcova R; Di Lenarda A; Barbati G; Sinagra G
    J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):669-77. PubMed ID: 20216227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left Ventricular Strain Is Abnormal in Preclinical and Overt Hypertrophic Cardiomyopathy: Cardiac MR Feature Tracking.
    Vigneault DM; Yang E; Jensen PJ; Tee MW; Farhad H; Chu L; Noble JA; Day SM; Colan SD; Russell MW; Towbin J; Sherrid MV; Canter CE; Shi L; Ho CY; Bluemke DA
    Radiology; 2019 Mar; 290(3):640-648. PubMed ID: 30561279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.